ATE497761T1 - Therapeutisches oder prophylaktisches mittel gegen leukämie - Google Patents

Therapeutisches oder prophylaktisches mittel gegen leukämie

Info

Publication number
ATE497761T1
ATE497761T1 AT07745501T AT07745501T ATE497761T1 AT E497761 T1 ATE497761 T1 AT E497761T1 AT 07745501 T AT07745501 T AT 07745501T AT 07745501 T AT07745501 T AT 07745501T AT E497761 T1 ATE497761 T1 AT E497761T1
Authority
AT
Austria
Prior art keywords
therapeutic
prophylactic agent
leukemia
agent against
prophylactic
Prior art date
Application number
AT07745501T
Other languages
English (en)
Inventor
Mie Kaino
Hiroyuki Meguro
Hiroe Hirokawa
Naoyoshi Yamamoto
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Application granted granted Critical
Publication of ATE497761T1 publication Critical patent/ATE497761T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/04—Seven-membered rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07745501T 2006-06-20 2007-06-19 Therapeutisches oder prophylaktisches mittel gegen leukämie ATE497761T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006169671 2006-06-20
PCT/JP2007/062282 WO2007148676A1 (ja) 2006-06-20 2007-06-19 白血病の治療又は予防剤

Publications (1)

Publication Number Publication Date
ATE497761T1 true ATE497761T1 (de) 2011-02-15

Family

ID=38833418

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07745501T ATE497761T1 (de) 2006-06-20 2007-06-19 Therapeutisches oder prophylaktisches mittel gegen leukämie

Country Status (11)

Country Link
US (1) US7893046B2 (de)
EP (1) EP2033637B1 (de)
JP (1) JP5136413B2 (de)
KR (1) KR101353879B1 (de)
CN (1) CN101472581B (de)
AT (1) ATE497761T1 (de)
AU (1) AU2007262083B2 (de)
CA (1) CA2655801C (de)
DE (1) DE602007012435D1 (de)
ES (1) ES2358291T3 (de)
WO (1) WO2007148676A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006306743A (ja) * 2005-04-26 2006-11-09 Hamamatsu Photonics Kk 体液処理方法
EP2268821A1 (de) * 2008-04-25 2011-01-05 New York Blood Center, Inc. Abi1/hssh3bp1-konditionale knockout-maus
JP5998933B2 (ja) * 2011-06-30 2016-09-28 東レ株式会社 グリシン誘導体の結晶及びその医薬用途
JPWO2014051056A1 (ja) * 2012-09-28 2016-08-22 東レ株式会社 グリシン誘導体の結晶及びその医薬用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2150550A1 (en) 1992-12-01 1994-06-09 Melissa S. Egbertson Fibrinogen receptor antagonists
EP0760658B1 (de) 1994-05-27 2002-11-13 Merck & Co. Inc. Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption
DE69817760T2 (de) * 1997-06-09 2004-08-05 KURARAY CO., LTD, Kurashiki Polymerisierbare zusammensetzung für dentalanwendungen
AU1411499A (en) 1997-11-20 1999-06-15 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
KR100675036B1 (ko) * 2000-08-18 2007-01-29 아지노모토 가부시키가이샤 신규한 페닐알라닌 유도체 및 이를 포함하는 의약품
JP4164871B2 (ja) * 2001-07-26 2008-10-15 味の素株式会社 新規フェニルプロピオン酸誘導体
JP4452899B2 (ja) * 2001-12-13 2010-04-21 味の素株式会社 新規フェニルアラニン誘導体
JP4470219B2 (ja) 2002-02-20 2010-06-02 味の素株式会社 新規フェニルアラニン誘導体
JP4233353B2 (ja) * 2002-02-27 2009-03-04 田辺三菱製薬株式会社 医薬組成物
US20050276803A1 (en) * 2004-04-16 2005-12-15 Genentech, Inc. Method for augmenting B cell depletion
AU2005320089B2 (en) * 2004-12-24 2011-04-07 Toray Industries, Inc. Glycine derivative and use thereof

Also Published As

Publication number Publication date
KR101353879B1 (ko) 2014-01-20
EP2033637B1 (de) 2011-02-09
KR20090036563A (ko) 2009-04-14
CA2655801A1 (en) 2007-12-27
JPWO2007148676A1 (ja) 2009-11-19
EP2033637A4 (de) 2009-11-11
CN101472581B (zh) 2011-06-08
JP5136413B2 (ja) 2013-02-06
CA2655801C (en) 2014-03-11
DE602007012435D1 (de) 2011-03-24
EP2033637A1 (de) 2009-03-11
US20090253724A1 (en) 2009-10-08
US7893046B2 (en) 2011-02-22
ES2358291T3 (es) 2011-05-09
WO2007148676A1 (ja) 2007-12-27
CN101472581A (zh) 2009-07-01
AU2007262083B2 (en) 2012-01-19
AU2007262083A1 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
ATE556061T1 (de) Therapeutisches oder prophylaktisches mittel gegen multiple sklerose
WO2006067165A3 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
WO2006049835A3 (en) Indole and benzimidazole derivatives
WO2006069155A3 (en) Inhibitors of protein arginine methyl transferases
CY1111693T1 (el) Αντιιικοι παραγοντες
NO20072515L (no) 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
EA201100795A1 (ru) Фармацевтическая композиция эффективного ингибитора всг для перорального введения
NO20080827L (no) Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon
EP1774968A4 (de) Benzylisochinolin-derivat oder bisbenzylisochinolin-derivat enthaltendes psychotropes mittel, analgetikum und/oder antiphlogistikum und nahrungsmittel zur förderung der gesundheit
GB0413087D0 (en) Therapeutic compounds
SE0402762D0 (sv) Indazole sulphonamide derivatives
NO20052908L (no) Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
WO2009041787A3 (en) Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper nigrum for the prevention and treatment of inflammatory disease
ATE497761T1 (de) Therapeutisches oder prophylaktisches mittel gegen leukämie
DK1228758T3 (da) Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom
MXPA06003122A (es) Composiciones farmaceuticas y procedimientos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y un agonista/antagonista de estrogenos.
WO2007146856A3 (en) Substituted gamma lactams as therapeutic agents
BRPI0513549A (pt) composições farmacêuticas para o tratamento de leishmaniose
WO2007047881A3 (en) Method for treating neuropathic pain
WO2003070153A3 (en) Stabilized pharmaceutical compositions of halofuginone and other quinazolinone derivatives
ATE508741T1 (de) Therapeutisches oder prophylaktisches mittel gegen allergische dermatitis
EP1747200B8 (de) Alkaloidverbindungen und ihre verwendung als antimalariamittel
WO2006076568A3 (en) Thiazolopyridines as cannabinoid receptor modulators

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties